The Journal of Experimental Medicine
Avanti Polar Lipids, Inc.
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents
Published online
doi:10.1084/jem.20090765
The Journal of Experimental Medicine, Vol. 206, No. 5, 977-980
The Rockefeller University Press, 0022-1007 $30.00
© Malynn et al.
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 889K)
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Malynn, B. A.
Right arrow Articles by Ma, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Malynn, B. A.
Right arrow Articles by Ma, A.
Related Collections
Right arrowRelated Article
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

COMMENTARY

 A20 takes on tumors: tumor suppression by an ubiquitin-editing enzyme

Barbara A. Malynn and Averil Ma

B.A.M. and A.M. are at Program in Biomedical Sciences, Program in Biological Sciences, Department of Medicine, University of California, San Francisco, San Francisco, CA 94143.

CORRESPONDENCE A.M.: averil.ma{at}ucsf.edu


ABSTRACT
Many B cell cancers are characterized in part by the dysregulation of the NF-{kappa}B signaling pathway. A new study identifies somatic mutations in TNFAIP3, the gene encoding the NF-{kappa}B inhibitor A20, in Hodgkin lymphomas and primary mediastinal lymphomas. These data reveal the role of A20 as a tumor suppressor protein.

© 2009 Malynn and Ma
This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.jem.org/misc/terms.shtml). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

Related Article

TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma
Roland Schmitz, Martin-Leo Hansmann, Verena Bohle, Jose Ignacio Martin-Subero, Sylvia Hartmann, Gunhild Mechtersheimer, Wolfram Klapper, Inga Vater, Maciej Giefing, Stefan Gesk, Jens Stanelle, Reiner Siebert, and Ralf Küppers
J. Exp. Med. 2009 206: 981-989. [Abstract] [Full Text] [PDF]



This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS